https://arolstar52-zhtest.hf.space/index.php?action=history&feed=atom&title=HSG4112
HSG4112 - 版本历史
2026-07-18T04:56:44Z
在这个wiki上该页的修订历史
MediaWiki 1.43.9
https://arolstar52-zhtest.hf.space/index.php?title=HSG4112&diff=4353262&oldid=prev
imported>Htmlzycq：/* top */
2025-04-18T02:51:47Z
<p><span class="autocomment">top</span></p>
<p><b>新页面</b></p><div>{{Infobox drug<br />
| drug_name = <br />
| INN = <br />
| type = <!-- empty --><br />
| image = Vutiglabridin.svg<br />
| alt = <br />
| caption = <br />
<!-- Clinical data --><br />
| pronounce = <br />
| tradename = <br />
| Drugs.com = <br />
| MedlinePlus = <br />
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --><br />
| pregnancy_AU_comment = <br />
| pregnancy_category= <br />
| routes_of_administration = <br />
| ATCvet = <br />
| ATC_prefix = <!-- 'none' if uncategorised --><br />
| ATC_suffix = <br />
<!-- Legal status --><br />
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --><br />
| legal_AU_comment = <br />
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 --><br />
| legal_BR_comment = <br />
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --><br />
| legal_CA_comment = <br />
| legal_DE = <!-- Anlage I, II, III or Unscheduled --><br />
| legal_DE_comment = <br />
| legal_NZ = <!-- Class A, B, C --><br />
| legal_NZ_comment = <br />
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --><br />
| legal_UK_comment = <br />
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --><br />
| legal_US_comment = <br />
| legal_EU = <br />
| legal_EU_comment = <br />
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --><br />
| legal_UN_comment = <br />
| legal_status = Investigational<!-- For countries not listed above --><br />
<!-- Pharmacokinetic data --><br />
| bioavailability = <br />
| protein_bound = <br />
| metabolism = <br />
| metabolites = <br />
| onset = <br />
| elimination_half-life = <br />
| duration_of_action= <br />
| excretion = <br />
<!-- Identifiers --><br />
| CAS_number = 1800188-47-9<br />
| CAS_number_Ref = {{cascite|correct|CAS}}<br />
| PubChem = 118204185<br />
| UNII = = 7AWD9J49UP<br />
| DrugBank = <br />
<!-- Chemical and physical data --><br />
| IUPAC_name = 2-(8,8-Dimethyl-3,4,9,10-tetrahydro-2''H''-pyrano[2,3-''h'']chromen-3-yl)-5-ethoxyphenol<br />
| C = 22 | H = 26 | O = 4<br />
| SMILES = OC1=CC(OCC)=CC=C1C2COC=3C(=CC=C4OC(C)(C)CCC43)C2<br />
}}<br />
<br />
'''Vutiglabridin'''（中文译名未知），开发代号'''HSG4112'''，是一种外消旋的有机化合物，化学式为[[C22H26O4|C<sub>22</sub>H<sub>26</sub>O<sub>4</sub>]]，为实验性抗肥胖药物，是[[光甘草定]]的结构类似物<ref>{{cite journal |last1=Hyeon |first1=Jooseung |last2=Lee |first2=Jihan |last3=Kim |first3=Eunju |last4=Lee |first4=Hyeong Min |last5=Kim |first5=Kwang Pyo |last6=Shin |first6=Jaejin |last7=Park |first7=Hyung Soon |last8=Lee |first8=Yun-Il |last9=Nam |first9=Chang-Hoon |title=Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions |journal=Experimental Gerontology |date=October 2023 |volume=181 |pages=112269 |doi=10.1016/j.exger.2023.112269|doi-access=free }}</ref><ref>{{cite journal |last1=Na |first1=Joo Young |last2=Yoon |first2=Deok Yong |last3=Yoo |first3=Hyounggyoon |last4=Lee |first4=SeungHwan |last5=Yu |first5=Kyung‐Sang |last6=Jang |first6=In‐Jin |last7=Yoo |first7=Sang‐Ku |last8=Kim |first8=Youngah |last9=Oh |first9=Jaeseong |title=Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study |journal=Clinical and Translational Science |date=November 2022 |volume=15 |issue=11 |pages=2744–2757 |doi=10.1111/cts.13401 |url=https://doi.org/10.1111/cts.13401 |language=en |issn=1752-8054|pmc=9652434 }}</ref><ref>{{cite journal |last1=Choi |first1=Leo Sungwong |last2=Jo |first2=In Geun |last3=Kang |first3=Ku Suk |last4=Im |first4=Jeong Ho |last5=Kim |first5=Jiyoung |last6=Kim |first6=Jinyoung |last7=Chung |first7=Jin Wook |last8=Yoo |first8=Sang-Ku |title=Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity |journal=International Journal of Obesity |date=January 2021 |volume=45 |issue=1 |pages=130–142 |doi=10.1038/s41366-020-00686-1 |url=https://www.nature.com/articles/s41366-020-00686-1 |language=en |issn=1476-5497 |doi-access=free |access-date=2023-12-14 |archive-date=2023-12-20 |archive-url=https://web.archive.org/web/20231220134105/https://www.nature.com/articles/s41366-020-00686-1 |dead-url=no }}</ref>。<br />
<br />
它可以5-羟基-2,2-二甲基-2''H''-1-苯并呋喃-6-甲醛为原料经多步反应制得<ref>Yoo, Sang Ku; Chung, Jin Wook; Jo, In Geun; Im, Jeong Ho; Kang, Ku Suk; Kim, Jin Young. Pyranochromenyl-phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease. 2015. WO2015099392{{ko}} / 2014. CN105849111A{{zh}} / 2016. US2016272650A1{{en}}.</ref>。<br />
<br />
==参考文献==<br />
{{reflist}}<br />
<br />
[[Category:苯酚]]<br />
[[Category:苯乙醚]]</div>
imported>Htmlzycq